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Abstract: Most patients with non-small-cell lung cancer (NSCLC) present with advanced 
disease and their long-term prognosis remains poor. Epidermal growth factor receptor (EGFR)-
targeted therapies, such as gefitinib, have been subjected to comprehensive clinical develop-
ment. Several phase II and III trials evaluated the clinical efficacy of gefitinib as monotherapy 
in pretreated patients with advanced NSCLC, as well as both monotherapy and combined with 
chemotherapy in chemotherapy-naive patients. A phase III trial (ISEL) in heavily pretreated 
advanced NSCLC patients demonstrated some improvement in survival with gefitinib compared 
with placebo; however, the difference was not statistically significant within the overall popula-
tion. A large phase III trial in pretreated patients (INTEREST) demonstrated the non-inferiority 
of gefitinib in comparison with docetaxel for overall survival, together with an improved quality 
of life and tolerability profiles. In a large phase III trial (IPASS) in Asian chemotherapy-naive, 
never or former light-smoker patients with adenocarcinoma, gefitinib was more effective than 
carboplatin–paclitaxel in prolonging progression-free survival, particularly in patients harboring 
EGFR gene mutations. Gefitinib was a generally well tolerated treatment, with skin rash and 
diarrhea being the most common treatment adverse events. As a result, gefitinib is expected 
to have a large impact on the management of patients with advanced NSCLC, in particular in 
EGFR mutated patients.
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Introduction
Lung cancer is still the main cause of cancer deaths in the world.1 Non-small-cell 
lung cancer (NSCLC) accounts for approximately 80% of all lung cancers and can 
be divided into three principal subtypes: adenocarcinoma, squamous-cell carcinoma 
and large cell carcinoma.2
At the time of diagnosis, about 75% of NSCLC patients present with locally 
advanced or metastatic disease.1 For most of these patients the only therapeutic option 
is based on chemotherapy alone. The aim of this treatment is to slow down the pro-
gression of the disease, to relieve the patients from the lung cancer symptoms and, 
whenever possible, to increase the overall survival.
A meta-analysis, published in 1995 and updated in 2008, affirmed the efficacy 
of first-line platinum-based chemotherapy in improving overall survival compared 
with best supportive care (BSC) in advanced NSCLC.3,4 Subsequently, survival 
differences were not demonstrated among the various platinum-based doublets, 
including a third-generation drug, such as paclitaxel, docetaxel, vinorelbine or 
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Recently, after the publication of the ECOG 4599 and 
AVAIL trial results, bevacizumab has been approved for the 
first-line treatment of non-squamous NSCLC in association 
with platinum-based chemotherapy.8,9 Moreover, pemetrexed 
has been recently registered for the first-line treatment of 
non-squamous NSCLC in association with cisplatin, after 
the results obtained by Scagliotti and colleagues in a trial 
demonstrating the non-inferiority of this new combination 
compared to standard cisplatin-gemcitabine.10
For second-line therapy, docetaxel and pemetrexed 
have been approved for this indication.11 The recent ASCO 
guidelines for the treatment of advanced NSCLC recommend 
also the use of gefitinib or erlotinib, epidermal growth fac-
tor receptor (EGFR)-tyrosine-kinase inhibitors (TKIs), in 
second- or third-line settings.12
Aiming to obtain an improvement in NSCLC manage-
ment and prognosis, researchers have investigated the role 
of molecular-targeted agents, such as inhibitors of specific 
cellular growth pathways, like that of EGFR and of vascular 
endothelial growth factor receptor (VEGFR).
EGFR is the cell-surface receptor for the epidermal 
growth factor family proteins. The interaction between the 
receptor and its ligands activates signal transduction pathways 
involved in cell proliferation and survival. Increased expres-
sion of EGFR has been found in 40%–80% of NSCLC.13 
Therefore, different approaches have been developed in order 
to inhibit EGFR, such as competition for the extracellular 
domain by monoclonal antibodies (cetuximab) or the inhibi-
tion of EGFR tyrosine-kinase activity by small-molecules 
interacting with the intracellular domain (erlotinib and gefi-
tinib). In this paper, we will review the phase II-III trial results 
obtained with gefitinib in the treatment of NSCLC.
Mode of action and 
pharmacokinetic of gefitinib
Gefitinib is an orally administered low-molecular-weight 
anilinoquinazoline that inhibits the phosphorylation and 
tyrosine-kinase activity of the intracellular ATP-binding 
domain of EGFR through competitive binding to this site. 
The inhibition of the receptor and its related downstream 
process is achieved at dosages of 250 mg/day, while the 
maximal tolerable dosage, assessed in phase I trials, is 
700 mg/day.14 Pharmacokinetic studies found that gefitinib 
is adsorbed slowly and it reaches peak plasma concentration 
after 3–7 hours. Because of its biological half-life of about 
28 hours, gefitinib is administered once in a day.15,16
Others trials were conducted in order to establish the 
tumor penetration of gefitinib. In one of these, gefitinib 
was administered orally for 28 days in patients with early 
NSCLC and, subsequently, the drug concentrations in sur-
gically resected tumor samples and plasma were compared; 
the drug concentrations were higher in the tissues than in the 
plasma, proving that gefitinib is able to penetrate into tumor 
tissue efficiently.17
Gefitinib is metabolized principally by cytochrome 
P4503A4, while CYP3A5 and CYP2D6 are less involved. 
This is the reason why gefitinib metabolism can differ from 
patient to patient; ie, in consideration of inter-individual 
variability of CYP3A4 expression and activity. Therefore, 
inducers or inhibitors of this cytochrome can also influence 
the pharmacokinetics of this drug.18
Some studies demonstrated that gefitinib blocks 
  selectively EGFR tyrosine-kinase (if compared with 
tyrosine-kinases of different receptors) and that it does 
not inhibit   serine-threonine-kinases.19 Its activity deter-
mines an upregulation of a cell cycle inhibitor (p27) and 
a downregulation of a transcription factor (c-fos), result-
ing in arresting the cell cycle in G1 phase.20 EGFR works 
through two   different downstream signaling pathways: 
MAP kinase cascade, that activates different genes linked 
to cell proliferation and survival, and PI3K-AKT cascade, 
in which phosphorylated AKT (p-AKT) inactivates pro-
apoptotic proteins. In some studies, gefitinib was found 
to be more active on tumors with enhanced basal p-AKT 
activity.21 Moreover; gefitinib decreases levels of important 
angiogenesis factors, like VEGF.22
Gefitinib as second- or third-line 
therapy
iDeAL (iReSSA Dose evaluation  
in Advanced Lung Cancer) 1 and 2 trials
According to results of four phase I studies,16,23–25 two large, 
dose-randomized, double-blind multicenter phase II trials 
(IDEAL-1 and IDEAL-2) were conducted to evaluate the 
activity of gefitinib, 250 mg/day versus 500 mg/day, in 
pretreated patients with advanced NSCLC.26,27
The IDEAL-1 study was conducted in Europe and   others 
countries (Japan, South Africa, Australia) and recruited 
210 patients, while IDEAL-2 enrolled 221 patients in US.26,27 
In the first study, activity and efficacy were similar between 
250 mg and 500 mg.26 The objective response rates (RR) were 
of 18.4% and 19%, respectively, with a disease control rates 
(DCR) of 54.4% versus 51.4%; median progression-free sur-
vival (PFS) was of 2.7 versus 2.8 months and median overall 
survival (OS) of 7.6 versus 8.0 months, for 250 and 500 mg, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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respectively. The symptom   improvement rate was 40.3% for 
the 250 mg group and 37% for the 500 mg group.
Similar results were obtained in the IDEAL-2 trial, in 
which there was no significant difference in patients who 
received either 250 or 500 mg dose of gefitinib in terms of 
symptom improvement (43% versus 35%), RR (12% versus 
9%) and OS (7 versus 6 months).27
In both IDEAL-1 and IDEAL-2, in .70% of respond-
ing patients, the response occurred within the first 4 weeks. 
The response rates were durable, with a median duration of 
13 months and 7 months for patients in IDEAL-1 and -2, 
respectively.26,27
Adverse events, such as skin reactions and diarrhea, were 
generally mild, reversible and manageable with a greater 
number of dose modifications or withdrawals in patients 
receiving gefitinib at dose of 500 mg.26,27
From these trials emerged the first evidence about the 
major efficacy of gefitinib in some specific subgroups of 
patients, such as female gender, adenocarcinoma histological 
subtype and Asian ethnicity. In particular, in IDEAL-2 the 
RR was greater in adenocarcinoma than in other histologies 
(13% versus 4%, P = 0.046) and in females compared with 
males (19% versus 3%, P = 0.001).27 In IDEAL-1, the odds 
of responders was almost 3.5 times higher for patients with 
adenocarcinoma than for patients with other tumor histolo-
gies (odds ratio, OR = 3.45, P = 0.021) and 2.5 times higher 
for females than males (OR = 2.65, P = 0.017). In this trial, 
moreover, the RR was higher for Japanese than non-Japanese 
patients (27.5% versus 10.4%, OR = 3.27, P = 0.0023).26
Therefore, gefitinib showed in these trials meaningful 
anti-tumor activity associated with rapid symptom relief 
and improvement of quality of life in pretreated patients 
with advanced NSCLC. Concomitantly, the 250 mg/day 
was safer and more tolerated than 500 mg/day dose. So, the 
250 mg once daily dose was chosen for subsequent studies 
and gefitinib was registered in US and Japan for patients with 
advanced NSCLC as a second- or third-line treatment.
Gefitinib versus placebo: ISEL (IRESSA 
Survival evaluation in Lung Cancer) trial
ISEL is a randomized, placebo-controlled, international 
multicenter phase III study designed to investigate the impact 
on survival of gefitinib versus best supportive care (BSC) as 
a second- or third-line treatment in patients with advanced 
NSCLC.28 In this trial 1,692 patients, who were refractory 
or intolerant to previous chemotherapy, were enrolled and 
assigned in a ratio of 2:1 to either gefitinib 250 mg/day 
(1,129) or placebo (563) plus BSC. The primary endpoint 
was survival in the overall population and in patients with 
adenocarcinoma subtype.
Differences in the median survival did not reach a sta-
tistical significance, either in the overall population and in 
patients with adenocarcinoma histology (Table 1). However, 
patients treated with gefitinib had a significantly higher RR 
and longer time to treatment failure (Table 1).
On preplanned subgroup analyses, a longer survival time 
was observed for patients treated with gefitinib who were 
never-smokers (P = 0.012) and of Asian origin (P = 0.01) 
(Table 1). To highlight the possible role of Asian ethnic-
ity as predictive factor of response to gefitinib, a subset 
analysis including patients of Asian origin (about 20% of 
treated population) demonstrated that patients treated with 
gefitinib had a significant improvement in survival rate 
(9.5 versus 5.5 months; P = 0.010), time to treatment fail-
ure (4.4 versus 2.2 months, P = 0.0084) and tumor response 
(12.4 versus 2.1%).29 Gefitinib was well tolerated (see below; 
“Safety and tolerability”).
Therefore, the results of the ISEL trial show that treat-
ment with gefitinib was not associated with a significant 
increase in overall survival either in the overall population 
or in adenocarcinoma co-primary population. This result 
was disappointing given the finding of the phase III erlotinib 
study (NCIC-BR.21) which showed a 2-month increase in 
survival in previously treated patients with NSCLC.30 Several 
explanations have been considered for the different results 
of the two trials. Different patient populations were enrolled 
in the two studies, due to differences in the eligibility criteria. 
The ISEL trial required patients to have progressed on the 
previous line of chemotherapy during treatment or within 
90 days, while the BR.21 trial did not. This may have unin-
tentionally selected a patient population in the ISEL trial that 
was more refractory to treatment and less likely to benefit 
from additional treatment. Another potential explanation is 
that a suboptimal dose of gefitinib was investigated in the 
ISEL trial. The decision to proceed with the 250 mg daily 
dose was based on a higher rate of toxicity with the 500 mg 
daily dose and the similar response rates for the two doses. 
In contrast, the BR.21 trial investigated erlotinib at the MTD 
(maximum tolerated dose). It is possible that cases that had 
limited sensitivity or were partially dependent on the EGFR 
pathway may have had a greater clinical benefit from the 
MTD dose of erlotinib than gefitinib, which was given at 
approximately 40% of the MTD. There has also been exten-
sive investigation into molecular markers that explain the 
significant difference in clinical outcomes associated with 
EGFR-TKI therapy. A difference in the prevalence of one Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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or more of the biomarkers associated with the response or 
resistance to EGFR-TKI therapy between the two trials may 
have contributed to the difference in the results.
A biological ISEL sub-study was performed including the 
assessment of EGFR gene copy number by fluorescent in situ 
hybridization (FISH), EGFR and p-AKT protein expression 
by immunohistochemistry (IHC), EGFR, K-RAS and B-RAF 
mutational status (Figure 1).31 It showed that a high EGFR 
gene copy number in patients treated with gefitinib represents 
a predictive factor of survival benefit when compared with 
placebo (HR: 0.61 versus 1.16 for high and low gene copy 
number, respectively; interaction test, P = 0.045), such as 
EGFR expression (HR: 0.77 versus 1.57 for positive and 
negative protein expression, respectively; interaction test, 
P = 0.049) (Table 1). Data on survival from the ISEL trial 
are consistent with the results from biological sub-study of 
BR.21 trial.32,33
In addition, patients with EGFR mutations obtained 
higher RR than wild-type patients (37.5% versus 2.6%). 
According to p-AKT, no correlation was observed in terms 
of survival; although there was a better RR in p-AKT posi-
tive patients treated with gefitinib when compared to p-AKT 
negative ones (10.1% versus 6.3%, respectively). Of 12 
patients with a K-RAS mutation, 6 were treated with gefitinib 
and no responses were seen, whereas no B-RAF mutations 
were detected.
Gefitinib versus chemotherapy
Phase ii study: SiGN (second line 
indication of gefitinib in NSCLC) trial
The SIGN was a phase II open-label randomized study, 
comparing gefitinib 250 mg/day (n = 60 patients) with 
docetaxel 75 mg/m2 every 3 weeks (n = 73 patients) in 
advanced pretreated NSCLC.34 The trial was not designed 
to test for a statistical difference between treatments on 
any endpoint its primary objective was symptom improve-
ment using the FACT-L questionnaire (see below “Quality 
of life”). The results suggest that gefitinib and docetaxel 
have similar activity and efficacy; (symptom improve-
ment rates of 36.8% and 26%; RR of 13.2% and 13.7%; 
median PFS of 3 and 3.4 months; median OS of 7.5 and 
7.1 months, with quality of life improvement rates of 33.8% 
and 26%, for gefitinib and docetaxel, respectively), with 
a more favorable tolerability profile for gefitinib (adverse 
events of all grades: 51.5% and 78.9%, of grade 3–4 
8.8% and 25.4%)
Table 1 Results of the iSeL trial28,31
Number of  
patients
RR 
(%)
P TTF 
(months)
HR  
[95% CI]
P OS 
(months)
HR 
[95% CI]
P
Results in overall population (n = 1,692)
Gefitinib 250 mg 1129 8.0
,0.0001
3.0 0.82 
[0.73–0.92]
0.0006
5.6 0.89 
[0.77–1.02]
0.087
Placebo 563 1.3 2.6 5.1
Results in adenocarcinoma subtype population (n = 812)
Gefitinib 250 mg 541 11.9
–
– – 
–
–
6.3 0.84 
[0.68–1.03]
0.089
Placebo 271 – – 5.4
Results in never–smoker subgroup population (n = 375)
Gefitinib 250 mg 250 18.1
–
5.6 0.55 
[0.42–0.72] ,0.0001
8.9 0.67 
[0.49–0.92] 0.012 Placebo 125 – 2.8 6.1
Results in Asian subgroup population (n = 342)
Gefitinib 250 mg 235 12.4
–
4.4 0.69 
[0.52–0.91]
0.0084
9.5 0.66 
[0.48–0.91]
0.010
Placebo 107 2.1 2.2 5.5
Results in patients with high EGFR gene copy number (n = 114)
Gefitinib 250 mg 235 16.4
–
4.5 0.55 
[0.34–0.89]
–
8.3 0.61 
[0.36–1.04]
0.067
Placebo 107 3 1.9 4.5
Results in patients with low EGFR gene copy number (n = 256)
Gefitinib 250 mg 235 3.2
–
2.4 1.25 
[0.92–1.72]
– 
4.3 1.16 
[0.81–1.64]
0.417
Placebo 107 0 3.9 6.2
Results in patients with EGFR protein expression positive (n = 264)
Gefitinib 250 mg 235 8.2
–
2.8 0.83 
[0.61–1.12]
–
5.5 0.77 
[0.56–1.08]
0.126
Placebo 107 1.5 3.2 4.6
Results in patients with EGFR protein expression negative (n = 115)
Gefitinib 250 mg 235 1.5
–
1.9 1.24 
[0.77–2.02]
– 
4.2 1.57 
[0.86–2.87]
0.140
Placebo 107 0 3.9 NR
Abbreviations: RR, response rate; TTF, time to treatment failure; HR, hazard ratio; CI, confidence interval; OS, overall survival; NR, not reached; –, data not available.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
85
Gefitinib treatment of non-small cell lung cancer
Phase iii studies: iNTeReST, v-15-32  
and iSTANA trials
Recently, the results of three phase III trials comparing 
gefitinib versus docetaxel in this setting have been published 
(Table 2).35–37
iNTeReST (iressa NSCLC trial evaluating  
response and survival versus taxotere) trial
The INTEREST trial compared gefitinib with docetaxel 
as second- or third-line therapy in 1,466 patients with 
advanced NSCLC treated with prior platinum-based che-
motherapy.35 The patients were randomly assigned on a 1:1 
basis to receive either gefitinib 250 mg/day or docetaxel 
75 mg/m2 every 3 weeks. The primary endpoints were the 
non-inferiority of gefitinib in comparison with docetaxel, in 
terms of overall survival in the total population and supe-
riority in patients who expressed a high EGFR gene copy 
number.
In the overall population, median OS was 7.6 months in 
the gefitinib group versus 8.0 months in the docetaxel group, 
with a 1-year survival of 32% versus 34%, respectively, 
demonstrating the non-inferiority of gefitinib with respect to 
docetaxel (HR, 1.020, 95% CI, 0.905–1.150, with the upper 
confidence limit less than the non-inferiority limit of 1.154) 
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Figure 1 Progression-free survival (PFS) and overall survival (OS) results (months) obtained with gefitinib in EGFR biomarker subgroups of ISEL and INTEREST trials.31,38
Abbreviations: PFS, progression-free survival; OS, overall survival; NA, not available; iHC, immunohistochemistry; EGFR FiSH positive, high gene copy number; EGFR FiSH 
negative, low gene copy number.
Table 2 Phase III trials of gefitinib versus chemotherapy as second-line treatment
Number of 
patients
RR 
(%)
P PFS 
(months)
HR 
[95% CI]
P OS 
(months)
HR 
[95% CI]
P
INTEREST trial (n = 1,433)35
Gefitinib 250 mg 733 9.1
0.33
2.2 1.04 
[0.93–1.18]
0.47
7.6 1.020 
[0.905–1.150]
–
Docetaxel 75 mg/m2 733 7.6 2.7 8.0
V-15-32 trial (n = 489)36
Gefitinib 250 mg 245 22.5
0.009
2.0 0.81 
[0.65–1.02]
0.77
11.5 1.12 
[0.89–1.40]*
0.330
Docetaxel 60 mg/m2 244 12.8 2.0 14.0
ISTANA trial (n = 161)37
Gefitinib 250 mg 82 28.1
0.0007
3.3 0.729 
[0.533–0.998]**
0.0441
14.1  0.870 
[0.613–1.236]
0.437
Docetaxel 60 mg/m2 79 7.6 3.4 12.2
Notes: *95.24% Ci. **90% Ci.
Abbreviations: RR, response rate; TTF, time to treatment failure; HR, hazard ratio; CI, confidence interval; OS, overall survival; NR, not reached; –, data not available; 
PFS, progression-free survival.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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(Table 2). Nevertheless, the survival superiority of gefitinib 
in the subgroup with high EGFR gene copy number was not 
proven (8.4 versus 7.5 months; HR, 1.09, 95% CI, 0.78–1.51, 
P = 0.62). Survival results were consistent across preplanned 
subgroups.
The median PFS and RR were similar in both treatment 
groups (Table 2), although gefitinib afforded a statistically 
significant higher rate of improvement in quality of life (see 
below “Quality of life”).
Moreover, gefitinib had a better tolerability profile; the 
most common gefitinib adverse events were skin reactions 
and diarrhea, whereas hematologic disorders (neutropenia 
grade 3–4 and febrile neutropenia), asthenia and alopecia 
were more likely to occur with docetaxel.
Recently, the results of a preplanned analysis of molecular 
predictors from the INTEREST trial have been published.38 
The biomarkers considered were EGFR gene copy number by 
FISH, EGFR protein expression by IHC, EGFR and K-RAS 
mutational status (Figure 1). Data obtained showed no sta-
tistically significant impact of these biomarkers in terms of 
OS. EGFR mutation positive patients had longer PFS (HR, 
0.16, 95% CI, 0.05–0.49, P = 0.001) and higher RR (42.1% 
versus 21.1%, P = 0.04) and patients with high EGFR copy 
number had higher RR (13% versus 7.4%, P = 0.04) with 
gefitinib versus docetaxel. These biomarkers do not appear 
to be factors for differential survival between gefitinib and 
docetaxel in this setting; however, subsequent treatments may 
have influenced the survival results. There was no statisti-
cally significant difference between gefitinib and docetaxel 
in biomarker-negative patients. This suggests that gefitinib 
can provide similar overall survival to docetaxel in patients 
across a broad range of clinical subgroups and that EGFR 
biomarkers such as mutation status may additionally identify 
which patients are likely to gain the greatest PFS and RR 
benefit from gefitinib.
v-15-32 trial
This phase III study compared gefitinib 250 mg/day with 
docetaxel 60 mg/m2 every 3 weeks in 489 Japanese patients 
with advanced NSCLC, who were treated with one or two 
prior chemotherapy regimens.36 Of the 489 patients enrolled, 
approximately 78% had adenocarcinoma histology, 38% 
were female and 32% were never-smokers.
The primary endpoint was the non-inferiority of gefi-
tinib in comparison with docetaxel in overall survival; the 
upper limit of the CI was required to be #1.25 in order to 
demonstrate non-inferiority. This trial demonstrated similar 
efficacy between gefitinib and docetaxel; however, it did not 
meet the primary endpoint of demonstrating non-inferiority 
(HR, 1.12, 95.24% CI, 0.89–1.40, P = 0.330) (Table 2). 
This result could be due to the small number of patients and 
to post-study cross-over (36% of patients treated with gefi-
tinib received subsequent docetaxel and 53% of docetaxel 
treated patients received subsequent gefitinib). In addition, 
the median PFS was 2.0 months in both treatment groups, 
whereas gefitinib was statistically superior to docetaxel in 
terms of RR (Table 2). Gefitinib also significantly improved 
the quality of life as compared to docetaxel. The disease 
control rates and symptom improvement were similar for 
the two treatments. Gefitinib was also better tolerated than 
docetaxel (see below “Safety and tolerability”).
iSTANA (iReSSA as second-line therapy  
in advanced NSCLC) trial
This was a phase III trial conducted in Korea that com-
pared gefitinib with docetaxel as a second-line treatment in 
161 patients with advanced NSCLC.37 Its primary endpoint 
was PFS.
PFS was found to be longer on gefitinib when com-
pared with docetaxel; the PFS HR for gefitinib derived 
from the primary unadjusted model was 0.729 (90% CI, 
0.533–0.988, one-sided P = 0.0441) and from the supportive 
adjusted model was 0.634 (90% CI, 0.459–0.875, one-sided 
P = 0.0134). Median PFS was 3.3 months in the gefitinib 
group and 3.4 months in the docetaxel group; the 6-month 
PFS rates were 32% and 13%, respectively. In terms of RR, 
gefitinib was statistically superior to docetaxel (Table 2). 
In the final analysis of OS, the HR was 0.870 (95% CI, 
0.613–1.236, P = 0.437). No significant differences were seen 
in the quality of life or symptom improvement rates between 
the two treatment groups. Gefitinib was well tolerated, was 
consistent with previous data and had fewer adverse events 
than docetaxel.
Therefore, gefitinib showed in this trial an advantage over 
docetaxel in terms of PFS and RR as a second-line treatment; 
however, it is necessary underline its limited sample size, 
smaller than other similar studies, and the patient selection 
(only Korean or Asian ethnicity patients with a high propor-
tion of never smokers and patients with adenocarcinoma 
histology).
Gefitinib versus docetaxel: a meta-analysis of four 
clinical trials
At the last American Society of Clinical Oncology (ASCO) 
Annual Meeting, Shepherd and colleagues presented a 
meta-analysis of the four previously reported randomized Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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trials, evaluating gefitinib versus docetaxel in unselected 
pretreated patients with advanced NSCLC (SIGN, INTER-
EST, V-15-32, and ISTANA trials).39 In this meta-analysis 
gefitinib showed similar OS (HR, 1.03, 95% CI, 0.93–1.13, 
P = 0.5773) and PFS (HR, 0.96, 95% CI, 0.87–1.05, 
P = 0.3784), with a statistically significant increase in the RR 
(13.6% versus 9%, OR, 1.65, 95% CI, 1.24–2.21, P = 0.0007) 
when compared with docetaxel. This meta-analysis adds to 
the weight of evidence that gefitinib and docetaxel show 
similar efficacy in pretreated patients with advanced NSCLC 
and further contributes to defining the risk-benefit profile of 
each treatment, which also considers tolerability and ease 
of administration.
Gefitinib as first-line therapy
Gefitinib in combination with 
chemotherapy: the failing experience  
of iNTACT-1 and iNTACT-2 trials
The results obtained with gefitinib as a single agent in IDEAL 
trials26,27 led some authors to test the drug in association with 
chemotherapy as front-line treatment in two randomized 
phase III trials, INTACT-1 and INTACT-2 (Iressa NSCLC 
Trial Assessing Combination Treatment).40,41
The rationale to test the efficacy of the gefitinib-
  chemotherapy association was given by evidence, in preclini-
cal studies, of interaction between gefitinib and cytotoxic 
drugs (in particular with cisplatin); ie, a different mechanism 
of action and favorable safety profile of gefitinib.42
Unfortunately, both studies failed to demonstrate a 
survival advantage when gefitinib was associated with che-
motherapy (Table 3). INTACT-1 was a three arm trial in 
which 1,093 patients were randomized to receive cisplatin 
and gemcitabine for 6 cycles plus gefitinib 500 mg/day, 
250 mg/day or placebo.40 Gefitinib was continued after 
  chemotherapy until progression or unacceptable toxicity. 
Most of the patients were enrolled in European (74%) and 
North American (12%) centers. The primary endpoint was 
overall survival. The results were quite disappointing; the 
gefitinib arms showed no differences in OS as compared with 
the placebo arm. No differences were observed for the time 
to progression (TTP) and RR (Table 3). Subgroup analysis 
for sex, histology and time on chemotherapy also did not 
show any survival difference.
INTACT-2 was a three arms trial in which 1,037 patients, 
mostly in the US, were randomized to receive carboplatin and 
paclitaxel for 6 cycles plus gefitinib 500 mg/day, 250 mg/
day or placebo.41 As in previous study the primary endpoint 
was OS. The results of this trial did not show any differ-
ences from those of INTACT-1 trial (Table 3). The subgroup 
analysis did not show any statistical difference in survival 
except for a slight trend toward improved survival for patients 
with adenocarcinoma; these patients received chemotherapy 
for more than 90 days in the gefitinib 250 mg/day arm, 
suggesting a possible effect of gefitinib monotherapy as 
maintenance therapy. However, this result was not observed 
in INTACT-1 study.
Two similar phase III trials assessing the efficacy of 
  erlotinib in association with chemotherapy (TRIBUTE and 
TALENT trials) were conducted at the same time as the 
INTACT studies and showed similar results, confirming 
the absence of any benefit in the addition of TKIs to chemo-
therapy as first-line treatment of advanced NSCLC.43,44
The two gefitinib trials, INTACT 1 and 2, were well 
designed, adequately powered, and well conducted. The 
conclusion that concomitant gefitinib administration does not 
add clinical benefit to conventional chemotherapy in NSCLC 
seems, therefore, irrefutable. Different theories have been 
formulated to explain this lack of efficacy. One hypothesis 
is that each agent works against the same cell subpopulation 
Table 3 Phase III trials of gefitinib in combination with chemotherapy as first-line treatment of advanced NSCLC (INTACT-1 and 2)
Number of patients RR (%) P TTP (months) P OS (months) P
INTACT-1 trial (n = 1,093)40
GP + Gefitinib 500 mg 365 50.3
–
5.5
0.76
9.9
0.45 GP + Gefitinib 250 mg 365 51.2 5.8 9.9
GP + Placebo 363 47.2 6.0 10.9
INTACT-2 trial (n = 1,037)41
PC + Gefitinib 500 mg 347 30.0
–
4.6
0.056
8.7
0.64 PC + Gefitinib 250 mg 345 30.4 5.3 9.8
PC + Placebo 345 28.7 5.0 9.9
Notes: in iNTACT-1 trial: G, gemcitabine 1250 mg/m2 d1, 8 and P, cisplatin 80 mg/m2 d1 every 3 weeks; gefitinib or placebo were administered daily in association with 
chemotherapy up to 6 cycles then alone until disease progression. in iNTACT-2 trial: P, paclitaxel 225 mg/m2 d1 and C, carboplatin AUC 6 d1 every 3 weeks; gefitinib or 
placebo were administered daily in association with chemotherapy up to 6 cycles then alone until disease progression.
Abbreviations: RR, response rate; TTP, time to progression; OS, overall survival; –, data not available.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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so that the effect is redundant. Another hypothesis is that the 
activity of one agent results in the loss of an intermediary 
molecule, which is essential to the function of the other agent. 
At present, the strongest hypothesis about the failure of the 
two studies seems to be that the patients were not selected 
for any of the known criteria that has later been discovered 
to be associated with a sensitivity to gefitinib, so that the 
population who was most likely to receive a real benefit 
from the agent (EGFR mutation) did not amount enough to 
statistically change the results obtained.
Gefitinib in elderly and poor-performance 
patients: iNviTe and iNSTeP trials
Considering its good toxicity profile, gefitinib has recently 
been tested as an alternative to single agent monotherapy in 
elderly and poor performance status (PS) NSCLC patients.
INVITE (IRESSA in NSCLC versus Vinorelbine Investi-
gation in the Elderly) trial is the first phase II study designed 
to test gefitinib in untreated elderly NSCLC patients com-
pared with a single agent, vinorelbine.45 In this study 196 
unselected patients aged .70 years were randomly assigned 
to receive gefitinib 250 mg/day until progression or vinorel-
bine for up to 6 cycles. The primary endpoint was PFS; this 
trial was designed to determine the superiority of gefitinib as 
compared with vinorelbine. The results showed no statistical 
difference in PFS (2.7 versus 2.9 months, HR 1.19, 95% CI, 
0.85–1.65, P = 0.310), OS (5.9 versus 8.0 months; HR 0.98, 
95% CI, 0.66–1.47), RR (3.1% versus 5.1%) and disease 
control rates (43.3% versus 53.5%) for gefitinib and vinore-
lbine, respectively. Overall, the quality of life improvement 
and pulmonary symptom improvement rates were in favor 
of gefitinib. As expected, gefitinib showed better tolerability 
profile than vinorelbine.
Although the present study was not designed to show 
equivalence between the two drugs, there was no statistical 
difference between the two treatments, suggesting that gefi-
tinib could represent an alternative to single-agent chemo-
therapy in elderly patients. It is important to underline that the 
totality of the population enrolled in this trial was unselected 
for the features that confer sensitivity to gefitinib; in fact, most 
of them were male (77%), smokers (82%) and with squamous 
cell carcinoma (48%) and this might explain the low percent-
age of responders. Most patients were analyzed for EGFR 
gene copy number by FISH; surprisingly, the 54 patients who 
were EGFR FISH positive benefited more from vinorelbine 
than from gefitinib (HR, 3.13, 95% CI, 1.45–6.76 for PFS 
and HR, 2.88, 95% CI, 1.21–6.83 for OS). This finding was 
unexpected and in contrast to previous observations.
The INSTEP (IRESSA NSCLC Trial Evaluating Poor 
PS Patients) trial was a phase II study, comparing gefitinib 
to BSC in untreated patients with PS  2, not eligible for 
chemotherapy.46 In this study, 201 patients were random-
ized to receive gefitinib 250 mg/day until progression or 
unacceptable toxicity or BSC. Primary endpoint was PFS. 
The results showed no statistical difference in outcome for 
patients treated with gefitinib, even though there was a small 
trend toward improved PFS, OS and RR in favor of gefitinib. 
HRs were 0.82 (95% CI, 0.60–1.12, P = 0.217) and 0.84 (95% 
CI, 0.62–1.15, P = 0.272), for PFS and OS, respectively. 
RR was 6% for gefitinib and 1% for placebo. No statistical 
difference was seen in the quality of life. In the subgroup of 
EGFR FISH positive patients (n = 32), gefitinib improved 
significantly PFS (HR, 0.29) and there was a trend toward an 
increase in OS. This trial failed to demonstrate a statistically 
significant benefit for first-line gefitinib compared with BSC 
in unfit patients; however, a number of reports from gefitinib 
expanded access program (EAP) suggest that gefitinib may 
have utility as first-line treatment in patients with poor PS 
or unwilling to receive chemotherapy.47
Gefitinib in selected patients
As indicated above, gefitinib, when used in unselected 
patients, allows only a modest response rate ranging from 
10% up to 20%. Nevertheless, it appears that a higher benefit 
can be obtained in some patient subgroups, such as females, 
never smokers, Asians and patients with adenocarcinoma 
histology. Although clinical characteristics may identify 
candidates for EGFR-TKIs, the ideal patient selection should 
mostly rely on biological tumor features, in particular in 
the presence of EGFR gene mutations. The most common 
mutations are exon 19 deletions and exon 21 point mutation 
(L858R), which can be found in approximately 10%–20% of 
NSCLC patients, more frequently in never smokers, women, 
Asians and with adenocarcinoma.48–50 These alterations 
in structure of the self-phosphorylating domain enhance 
EGFR activation and also favor binding of TKIs to their 
site of action. Patients who harbor these mutations experi-
ence response rates higher than 65% and median survival 
of 20–30 months, as demonstrated in several retrospective 
studies.51–55 Such results led investigators to test gefitinib as 
a first-line therapy in EGFR mutated patients in prospective 
trials.
Phase ii studies
Several phase II trials investigated the efficacy of gefi-
tinib as a first-line treatment in highly selected patient Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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  populations, based on the presence of activating EGFR gene 
mutations.56–60
In a phase II trial, Asahina and colleagues obtained a 
RR of 75% and median PFS of 8.9 months.56 Inoue and col-
leagues evidenced similar results in 16 patients with EGFR 
mutated, identified among 75 chemonaive patients (RR of 
75%, with a DCR of 88% and a median PFS time of 9.7).57 
Yang and colleagues enrolled 106 patients selected by clini-
cal features and determined their EGFR mutation status in 
90 of these patients. Exon 19 deletions and L858R muta-
tions were present in 43 patients; the RR and median time 
to treatment failure were 95% and 8.9 months, respectively, 
for exon 19 deletions, and 73.9% and 9.1 months for L858R 
mutation.58
Similar results were obtained also in Caucasian patients. 
Sequist and colleagues (the iTARGET trial) selected 
chemonaive patients with non-squamous histology who 
had one or more clinical characteristics associated with 
activating EGFR mutations (low or never smoking history, 
adenocarcinoma histology, female gender and East Asian 
ethnicity).59 In this clinically enriched patient population, 
mutations were identified in 35% of patients, which is 
higher than the rate of 10%–15% seen in previous stud-
ies of Western populations.58 Thirty-one patients received 
gefitinib: RR was 55%, median PFS was 9.2 months, OS 
17.5 months, with 1-year survival of 73%. Two patients 
with classic activating mutations exhibited de novo gefitinib 
resistance and had concurrent genetic anomalies usually 
associated with acquired TKI resistance, specifically the 
T790M EGFR mutation and MET amplification. This study 
has demonstrated that genotype-directed EGFR-TKI therapy 
with gefitinib for patients with previously untreated NSCLC 
is feasible in a Western population.
Considering the favorable safety profile, Inoue and col-
leagues tested gefitinib in a phase II trial in NSCLC patients 
with poor PS harboring EGFR mutations, not eligible for 
chemotherapy.60 Thirty patients with NSCLC and poor PS, 
including 22 patients with PS 3 to 4, were enrolled. The over-
all RR was 66%, with a DCR of 90%. PS improvement rate 
was 79%. The median PFS and OS were 6.5 and 17.8 months, 
respectively. Despite the fact that most of these patients had 
aggressive disease, treatment with gefitinib in this setting 
yielded a median survival three- to four-fold higher than that 
generally observed with conventional cytotoxics. This is the 
first report indicating that EGFR mutation-positive patients 
with extremely poor PS benefit from first-line gefitinib. 
Because there has previously been no standard treatment for 
these patients with short-life expectancy, other than BSC, 
examination of EGFR mutations as a biomarker should be 
recommended in this patient population.
All these studies demonstrated an advantage in the use of 
gefitinib as first-line therapy in selected patients harboring 
EGFR activating mutations, achieving outcome results, which 
are higher than any other treatment used in NSCLC. Other 
prospective trials showed similar results in EGFR mutated 
NSCLC populations in further lines of treatment.61–65
Additional trials have selected patients based on a 
combination of clinical, pathological or molecular fea-
tures. The ONCOBELL trial selected patients who were 
never smokers or who had evidence of a high gene copy 
on FISH and were p-AKT positive.66 Of the 183 patients 
who were evaluated, 42 patients were enrolled in the trial 
and treated with gefitinib. The RR observed was 47.6%, the 
median TTP was 6.4 months and the 1-year survival rate 
was 64.3%. EGFR mutations were detected in 24 patients 
(66.8%) and the RR observed in those patients was 62.5%. 
The Southwest Oncology Group performed a phase II trial 
for patients with bronchioalveolar carcinoma.67 This trial 
included previously treated (n = 22) and untreated (n = 69) 
patients that received gefitinib at a dose of 500 mg daily. 
The RR in the previously treated and untreated patients 
was 9% and 17%, respectively, and the PFS times were 3 
and 4 months, respectively. Another area of investigation 
is the selection of patients based on the clinical history of 
non-smoking. A phase II trial investigated the activity of 
gefitinib (250 mg daily) in 37 chemotherapy-naive Korean 
patients with adenocarcinoma histology and a never smoking 
history.68 The observed RR was 69%, with a DCR of 81%. 
The median PFS time and 1-year survival rate observed were 
33 weeks and 73%, respectively.
Phase iii studies: iPASS, First-SiGNAL,  
wJTOG3405 and NeJ002 trials
According to the results obtained with gefitinib as a first-line 
treatment in phase II trials performed in selected popula-
tions, four Asian randomized phase III trials (IPASS, First-
SIGNAL, WJTOG3405 and NEJ002) were conducted to 
assess whether gefitinib could represent a valid alternative 
to chemotherapy in this setting of disease.69–72
iPASS (iressa Pan-Asia Study) trial
The IPASS trial was a randomized phase III study where 
previously untreated patients in East Asia who had advanced 
pulmonary adenocarcinoma and who were non-smokers or 
former light smokers were randomized to receive gefitinib 
or carboplatin-paclitaxel.69Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Eligible patients were chemotherapy-naive with NSCLC 
with adenocarcinoma histology, never (,100 cigarettes in 
lifetime) or light ex-smokers (stopped  15 years ago and 
smoked # 10 pack years) and with a performance status of 
0 to 2. A total of 1,217 patients were randomized to receive 
either gefitinib (250 mg/day; n = 609) until disease progres-
sion or other criteria for discontinuation or carboplatin (AUC 
5 or 6) and paclitaxel (200 mg/m2 every 3 weeks) (n = 608) 
for a maximum of 6 cycles or until disease progression or 
other criteria for discontinuation.
The primary objective was to assess the non-inferiority of 
gefitinib versus carboplatin-paclitaxel for PFS. Exploratory 
objectives were to evaluate the efficacy outcomes in bio-
marker subgroups defined by EGFR mutation status, EGFR 
gene copy number by FISH and EGFR IHC expression.
The study exceeded the primary objective and dem-
onstrated superiority of gefitinib relative to carboplatin-
paclitaxel in terms of PFS in the intent-to-treat population 
(Table 4). The HR was 0.74 (95% CI, 0.65–0.85, P < 0.001). 
Median PFS was 5.7 versus 5.8 months in gefitinib and che-
motherapy group, respectively, with 12-month rates of PFS 
of 24.9% versus 6.7%. Therefore, the risk of progression 
was reduced by 26% on gefitinib compared with carboplatin-
paclitaxel; however, the hazard ratio was not constant over 
time. Because of the crossing of the curves, the median PFS 
is similar on both treatments, although clearly it is not a good 
reflection of the treatment effect in this study. In fact, the 
pattern of the 4, 6 and 12-month progression-free rates favor 
  carboplatin-paclitaxel for the first 6 months and gefitinib for 
the remaining 16 months. The PFS treatment effect was con-
sistent with the overall population in all clinical subgroups.
At the time of data cut-off, for the primary analysis 
(14 April 2008), the data were immature as there were only 
450/1217 deaths (37%). Follow-up for survival is ongoing. 
OS was similar between the gefitinib and carboplatin-
paclitaxel arms and may be influenced by the large amount 
of subsequent therapy received in this study, making these 
data difficult to interpret. Objective RR was significantly 
higher with gefitinib (43.0%) than with carboplatin-paclitaxel 
(32.2%) (OR, 1.59, 95% CI, 1.25–2.01, P , 0.001).
Another important finding of the study was the result 
obtained in the subgroup of patients that were positive for 
EGFR mutation. In IPASS, 261 patients (59.7% of those with 
a known status) were mutation positive, the largest group 
ever studied in a randomized controlled trial of an EGFR-
TKI to date, reflecting the clinical selection of the patients 
in this study (Figure 2). Some striking differences in PFS 
outcome by EGFR mutation status were seen (interaction 
test, P , 0.0001). PFS was significantly longer for gefitinib 
than carboplatin-paclitaxel in mutation positive patients 
(HR, 0.48, 95% CI, 0.36–0.64, P , 0.001), while it was 
significantly longer for chemotherapy in mutation negative 
patients (HR, 2.85, 95% CI, 2.05–3.98, P , 0.001). Within 
these subgroups, the treatment effect appears to be constant 
over time, unlike in the overall study population. Among 
the EGFR mutation negative patients, over half of those 
receiving gefitinib had progressed by the time of the first 
scheduled scan at 6 weeks and this is likely to be driving the 
initial disadvantage for gefitinib in the overall population 
curves, with the later advantage being driven by the very 
long PFS for gefitinib in EGFR mutation positive patients. 
The EGFR mutation positive benefit outweighs the EGFR 
Table 4 Phase III trials of gefitinib versus chemotherapy as first-line treatment in clinically selected patients
Number of 
patients
RR 
(%)
P PFS 
(months)
HR 
[95% CI]
P OS 
(months)
HR 
[95% CI]
P
IPASS trial (n = 1,217)69
Gefitinib 609 43
,0.001
5.7 0.74 
[0.65–0.85]
,0.001
18.6 0.91 
[0.76–1.10]
–
PC 608 32.2 5.8 17.3
Results in EGFR mutation positive patients (n = 261)69
Gefitinib 132 71.2
,0.001
9.5 0.48 
[0.36–0.64]
,0.001
– 0.78 
[0.50–1.20]
–
PC 129 47.3 6.3 –
First-SIGNAL trial (309)70
Gefitinib 159 53.5
0.153
6.1 0.813 
[0.641–1.031]
0.044
21.3 1.003 
[0.749–1.343]
0.428
GP 150 45.3 6.6 23.3
Results in EGFR mutation positive patients (42)70
Gefitinib 26 84.6
0.002
8.5 0.613 
[0.308–1.221]
0.084
30.6 0.823 
[0.352–1.922]
0.648
GP 16 37.5 6.7 26.5
Notes: In IPASS trial: Gefitinib 250 mg/day; P, paclitaxel 200 mg/m2 d1 and C, carboplatin AUC 5 or 6 d1 every 3 weeks. In FIRST-SIGNAL trial: Gefitinib 250 mg/day;   
G, gemcitabine 1250 mg/m2 d1, 8 and P, cisplatin 80 mg/m2 d1 every 3 weeks.
Abbreviations: RR, response rate; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; –, data not available.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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mutation negative deficit, leading to overall superiority for 
gefitinib.
A post-hoc analysis of overall survival by mutation 
status was also performed, acknowledging that there would 
only be a small number of events in the analysis and hence 
limited power (only 37% of patients had died). The hazard 
ratio was numerically in favor of gefitinib in the EGFR 
mutation positive patients (based on 81 events; HR, 0.78, 
95% CI, 0.50–1.20) and numerically in favor of carboplatin-
paclitaxel in EGFR mutation negative patients (based on 94 
events; HR, 1.38, 95% CI, 0.92–2.09). However, no statisti-
cally significant differences were seen, possibly because the 
number of events was small.
In the EGFR mutation positive subgroup, RR was 
significantly higher with gefitinib (71.2%) than with carbo-
platin-paclitaxel (47.3%) (P , 0.001), while in the EGFR 
mutation negative subgroup, RR was significantly higher 
with carboplatin-paclitaxel (23.5%) than with gefitinib 
(1.1%) (P = 0.001).
About other biomarkers, a possibly related trend 
was observed with EGFR gene copy number (interac-
tion test, P = 0.0437), with a significant advantage for 
gefitinib over carboplatin-paclitaxel in patients with high 
EGFR gene copy number tumors (HR, 0.66, P = 0.005), 
while in patients with low gene copy number there was a 
numerical advantage for carboplatin-paclitaxel (HR, 1.24, 
P = 0.237). Post-hoc analysis suggests this effect was 
driven by the overlap of high EGFR gene copy number 
with a positive EGFR mutation status. Objective RR was 
also significantly higher with gefitinib in the subgroup 
of patients with high EGFR gene copy number (58.9% 
versus 44.8% P = 0.024). In the EGFR expression posi-
tive subgroup, objective response rate tended to be higher 
with gefitinib than with carboplatin-paclitaxel, but the 
difference was not statistically significant (51.5% versus 
41.8%, P = 0.109).
Quality of life improvement rates were significantly 
higher with gefitinib than carboplatin-paclitaxel; while 
similar proportions of patients on both treatments expe-
rienced an improvement in lung cancer symptoms (see 
below “Quality of life”). As expected, gefitinib was much 
better tolerated than chemotherapy (see below “Safety and 
tolerability”).
First-SiGNAL (First-line single agent  
iressa versus gemcitabine and cisplatin trial 
in never-smokers with adenocarcinoma 
of the lung) trial
Recently, results from a similar trial, comparing gefitinib 
with cisplatin-gemcitabine as first-line treatment in Asian 
never-smokers, with advanced adenocarcinoma, have been 
reported.70 Three hundred and nine patients, mostly women 
(89%), were randomly allocated 1:1 to gefitinib 250 mg/day 
(n = 159) until disease progression or other criteria for discon-
tinuation, or cisplatin-gemcitabine (n = 150) for a maximum 
of 6 cycles or until disease progression or other criteria for 
discontinuation. The primary endpoint was OS (Table 4).
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Figure 2 Progression-free survival (PFS) results (months) in EGFR mutated subgroups in iPASS, First-SiGNAL, wJTOG3405 and NeJ002 trials.69–72
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In the overall population, RR was 53.5% for gefitinib and 
45.3% for chemotherapy (OR, 1.385, 95% CI, 0.885–2.167, 
P = 0.153). The median OS and PFS were nearly identical, 
with a 1-year PFS rate of 20.3% versus 5.0%. The PFS sur-
vival curves were very similar to IPASS curves, with analogue 
crossing. Similarly to other studies, gefitinib improved quality 
of life with a better toxicity profile than chemotherapy.
The authors also conducted a subgroup study for EGFR 
mutations (Figure 2). Over 30% of patients were analyzed 
for mutation status, giving an overall EGFR mutation rate of 
43.8% (42 out of 96 patients). RR was 84.6% versus 37.5% 
(P = 0.002) for gefitinib and chemotherapy respectively in 
mutation positive patients, and 29.9% versus 51.9% in muta-
tion negative (P = 0.051). There was no difference in OS by 
mutation status; however, there was some difference in PFS 
favoring gefitinib in mutation positive patients (8.5 versus 
6.7 months; HR, 0.613, 95% CI, 0.308–1.221, P = 0.0849).
The absence of difference in OS, both in the overall 
and EGFR mutated populations, is most likely due to the 
post-study use of EGFR-TKIs in 80.7% of chemotherapy 
arm. Even if the study failed to reach its endpoint gefi-
tinib allowed the achievement of a favorable response 
rate and disease control in Asian, non-smoker patients; 
especially in those who carry the EGFR mutations, so 
it could represent a reasonable first-line therapy for this 
group of patients.
These two studies highlight the importance of a selection 
of the patients, who are candidates for receiving gefitinib 
therapy. Some clinical features are related to a high rate of 
EGFR mutation, so it is reasonable to consider the research 
of these mutations in patients with these characteristics to 
evaluate the appropriate timing for treatment with gefitinib. 
Two phase III Japanese studies have been performed specifi-
cally in patients EGFR mutated to compare the efficacy of 
gefitinib versus chemotherapy in the first-line treatment of 
NSCLC (WJTOG3405 and NEJ002 trials).71,72
wJTOG3405 (west Japan Thoracic 
Oncology Group3405) and NeJ002 
(North East Japan Gefitinib Study 
Group002) trials
In the WJTOG3405 trial, 172 EGFR mutated patients were 
randomly assigned to receive gefitinib or chemotherapy 
with cisplatin-docetaxel (Figure 2).71 The primary endpoint 
was PFS. The study met its endpoint, showing a median 
PFS of 9.2 months in the gefitinib group and 6.3 months in 
the chemotherapy group (HR, 0.489, 95% CI, 0.336–0.710, 
P , 0.0001). In the IPASS trial, PFS curves were similar in 
the gefitinib and the chemotherapy groups during the first 
6 months of treatment, while in the present study the curves 
favor gefitinib at any time of treatment. RR was 62.1% 
and 32.2% with gefitinib and chemotherapy, respectively 
(P , 0.0001). The OS data were not available at the time 
of publication. A subgroup study on mutation-type-specific 
survival showed no statistical difference between 19 deletions 
and exon 21 mutations.
The WJTOG3405 trial results confirm once more gefi-
tinib to be superior to chemotherapy in terms of RR and 
PFS in patients with EGFR mutations. Another prospec-
tive phase III study, comparing gefitinib to chemotherapy 
(carboplatin-paclitaxel) as first-line treatment in advanced 
NSCLC patients selected for EGFR mutation, was presented 
by Kobayashi and colleagues at the ASCO meeting 2009.72 At 
present, only data on PFS and RR from an interim analysis 
are available. Median PFS resulted of 10.4 months in the 
gefitinib arm (n = 98) and 5.5 months in the chemotherapy 
arm (n = 96) (HR, 0.357, 95% CI, 0.25–0.51, P , 0.001). 
Also significantly higher RR was obtained in gefitinib arm 
(74.5% versus 29%, P , 0.001).
Gefitinib as maintenance therapy
Due to its efficacy in advanced pretreated NSCLC patients 
and its mild toxicity profile, gefitinib has also been considered 
as maintenance therapy. Two trials tested gefitinib in unse-
lected patients subsequently to chemotherapy (WJTOG0203) 
and to chemo-radiotherapy (SWOG S0023).73,74
In the West Japan Thoracic Oncology Group Trial 
0203 trial, 604 patients were randomly assigned to receive 
a platinum-doublet chemotherapy for up to 6 cycles or the 
same doublet for 3 cycles followed by gefitinib as mainte-
nance therapy until progression.73 The trial failed to meet 
the primary endpoint of improving OS, as there was no 
statistical difference between the two arms (HR, 0.86, 95% 
CI, 0.72–1.03, P = 0.11). A small but significant improvement 
was seen in PFS (4.6 versus 4.3 months in gefitinib and che-
motherapy arm, respectively (HR, 0.68, 95% CI, 0.57–0.80, 
P , 0.001). In a subset analysis, a small significant differ-
ence in OS was found in the group of adenocarcinomas (HR, 
0.79, 95% CI, 0.65–0.98, P = 0.03). The explanation of these 
results could be related to the absence of any biological or 
clinical patient selection. It might be expected that there 
would be a greater efficacy in patients with EGFR mutation; 
nevertheless, it is uncertain whether there would be any 
benefit, administering gefitinib right after chemotherapy or 
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The South Western Oncology Group study evaluated 
the efficacy of a sequential therapy with gefitinib follow-
ing chemo-radiotherapy in unresectable locally advanced 
NSCLC.74 Patients were randomized to receive gefitinib or 
placebo after chemotherapy with cisplatin-etoposide for 2 
cycles with concomitant radiotherapy followed by 3 cycles 
of docetaxel consolidation. The primary endpoint was to 
achieve a 33% increase in median survival time rate. The 
study was closed after an unplanned interim analysis which 
showed that the planned objective was ruled out with a 
P = 0.0015.
At the time of the publication, coincident with a median 
time of follow up of 27 months, the median OS of gefitinib 
arm (n = 118) was 25 months compared to 32 months of 
placebo arm (n = 125) (P = 0.013). These results surpris-
ingly showed gefitinib to be detrimental in locally advanced 
NSCLC patients after a standard chemo-radiotherapy. It is 
hard to understand the reasons of these findings. A higher 
rate of toxic events was reported in the experimental arm, 
although the moderate intensity of adverse events cannot 
explain the detrimental effect. Furthermore, toxicity related 
deaths rate was only 2% in experimental arm. The lack of 
selection might have contributed to the poor efficacy of 
gefitinib and partially explains the results, although not the 
reduction in OS. Another hypothesis is the potential interac-
tion between EGFR inhibitors and radiotherapy. It is known 
that the concomitant use of these agents with radiotherapy 
enhance radiation efficacy, and it is also known that some 
people previously treated with radiotherapy have shown an 
impaired response to gefitinib.75,76 However, this hypothesis 
cannot completely explain the results of this study and the 
reasons of this detrimental effect remain unknown.
At present gefitinib has no indication as maintenance 
therapy in patients treated with standard therapy. It is possible 
that EGFR mutated patients could benefit from a maintenance 
therapy with gefitinib, although further trials on selected 
patients are required.
Safety and tolerability
Gefitinib is generally well tolerated, particularly in elderly and/
or poor PS patients; it is responsible for relatively few severe 
side effects, as compared with conventional chemotherapeutic 
agents. The most common side effects are skin rash and diar-
rhea; less common are nausea, vomiting and anorexia. Another 
common toxicity is the elevation of AST/ALT, which usually 
regresses after discontinuation of therapy (Table 5).
Interstitial lung disease (ILD) is a rare and potentially life-
threatening side effect of gefitinib, which has been reported 
in some studies. The incidence of gefitinib-induced ILD 
is consistently higher in Japan (1.6%–3.5%) as compared 
with other parts of the world (0.3%), although the reason 
for this geographic difference is unclear.76,77 A retrospective 
analysis of 112 patients with NSCLC treated with gefitinib 
found preexisting pulmonary fibrosis to be an important 
risk factor for developing fatal ILD.76 Another retrospective 
analysis of 1,976 Japanese patients with NSCLC treated with 
gefitinib showed positive smoking history, male gender and 
the coincidence of interstitial pneumonia to be significantly 
associated with gefitinib-induced ILD.77
The studies reported in this article have shown evidence of 
tolerable toxicity profile for gefitinib (in Table 5 we report the 
toxicity data of the three largest studies: ISEL,   INTEREST 
and IPASS trials).28,35,69
In the ISEL trial, the most common adverse events in the 
gefitinib group were of grade 1–2, whereas those of grade 
3–4 were similar for gefitinib and placebo (30% versus 
27%), with the same rate of ILD being just 1%.28 Only 5% 
of patients treated with gefitinib experienced adverse events 
leading to withdrawal.
The INTEREST trial showed serious adverse events in 
4% of patients receiving gefitinib and 18% receiving doc-
etaxel; this led to a lower rate of drug discontinuation for 
gefitinib (4% versus 11%) and a lower rate of adverse events 
leading to death (1% versus 2%).35 The most common toxici-
ties seen in the docetaxel group were hematological events: 
neutropenia (in 73.7% of cases with 10.1% of febrile neu-
tropenia); asthenia (46.7%); alopecia (35.5%); neurotoxicity 
(23.9%); and fluid retention (15.7%). Skin rash and diarrhea 
were the main adverse effects seen in the gefitinib group 
which occurred in 49.4% and 35%, respectively. Interstitial 
lung disease was 1% in both arms.
In the similar Japanese study (V-15-32) adverse events 
were consistent with those previously described; 76.2% of 
patients receiving gefitinib experienced rash of all grades 
(with 0.4% of grade 3–4) and 51.6% experienced diarrhea 
of all grades (with 2% of grade 3–4).36 ILD events were 
described in 5.7% of patients receiving gefitinib compared 
to 2.9% in the docetaxel group.
In the IPASS trial, the rate of grade 3–4 toxicities was 
28.7% for gefitinib and 61% for chemotherapy.69 This led 
to a lower rate of dose modification (16.1% versus 35.2%) 
and discontinuation of treatment (6.9% versus 13.6%). 
Treatment related deaths were 3.8% in the gefitinib arm and 
2.7% in the chemotherapy arm; 16 (2.6%) patients treated 
with gefitinib developed ILD versus 8 (1.4%) treated with 
chemotherapy. The most common adverse events were Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 5 Toxicity data of iSeL, iNTeReST and iPASS trials28,35,69
ISEL trial28
All grades Grade 3–4
Gefitinib (1,126) Placebo (562) Gefitinib (1,126) Placebo (562)
Skin rash 413 (37%)  56 (10%) 18 (2%)  1
Diarrhea 309 (27%)  52 (9%) 31 (3%)  5 (1%)
Nausea 190 (17%)  90 (16%) 9 (16%)  2
Anorexia 193 (17%)  77 (14%) 26 (2%)  11 (2%)
vomiting 152 (14%)  56 (10%) 13 (1%)  2
Dry skin 128 (11%)  20 (4%) 0 0
Pruritus 93 (8%)  27 (5%) 4 1
INTEREST trial35
  All grades Grade 3–4
  Gefitinib (729) Docetaxel (715) Gefitinib (729) Docetaxel (715)
Skin rash 360 (49.4%) 73 (10.2%) 15 (2.1%) 4 (0.6%)
Diarrhea 255 (35.0%)  177 (24.8%) 18 (2.5%)  22 (3.1%)
Asthenia 182 (25.0%) 334 (46.7%) 32 (4.4%)  64 (9.0%)
Dry skin 111 (15.2%)  10 (1.4%) 0 0
Nausea 148 (20.3%)  187 (26.2%) 3 (0.4%)  9 (1.3%)
Neutropenia 35 (5.0%)  514 (73.7%) 15 (2.2%)  406 (58.2%)
Febrile neutropenia 9 (1.2%)  72 (10.1%) 9 (1.2%)  72 (10.1%)
Pyrexia 69 (9.5%)  118 (16.5%) 2 (0.3%)  4 (0.6%)
Neurotoxicity 49 (6.7%)  171 (23.9%) 1 (0.1%)  17 (2.4%)
Myalgia 24 (3.3%)  113 (15.8%) 1 (0.1%)  4 (0.6%)
Anemia 34 (4.7%)  84 (11.7%) 11 (1.5%)  15 (2.1%)
Alopecia 23 (3.2%)  254 (35.5%) 0 0
Fluid retention 48 (6.6%)  112 (15.7%) 0 5 (0.7%)
IPASS trial69
All grades Grade 3–4
Gefitinib (607) Carboplatin-paclitaxel (589) Gefitinib (607) Carboplatin-paclitaxel (589)
Skin rash 402 (66.2%)  132 (22.4%) 19 (3.1%)  5 (0.8%)
Diarrhea 283 (46.6%)  128 (21.7%) 23 (3.8%)  8 (1.4%)
Anorexia 133 (21.9%)  251 (42.6%) 9 (1.5%)  16 (2.7%)
Dry skin 145 (23.9%)  17 (2.9%) 0  0
Pruritus 118 (19.4%) 74 (12.6%) 4 (0.7%)  1 (0.2%)
Stomatitis 103 (17.0%)  51 (8.7%) 1 (0.2%)  1 (0.2%)
Asthenia 102 (16.8%)  259 (44.0%) 2 (0.3%)  11 (1.9%)
Alopecia 67 (11.0%)  344 (58.4%) 0 0
Myalgia 47 (7.7%)  186 (31.6%) 3 (0.5%)  10 (1.7%)
Arthralgia 39 (6.4%)  113 (19.2%) 1 (0.2%)  6 (1.0%)
Nausea 101 (16.6%)  261 (44.3%) 2 (0.3%)  9 (1.5%)
vomiting 78 (12.9%)  196 (33.3%) 1 (0.2%)  16 (2.7%)
Neutropenia NA NA 22 (3.7%)  387 (67.1%)
Febrile neutropenia 1 (0.2%)  17 (2.9%) 1 (0.2%)  17 (2.9%)
Constipation 73 (12.0%) 173 (29.4%) 0  1 (0.2%)
Neurotoxicity 66 (10.9%)  412 (69.9%) 2 (0.3%)  29 (4.9%)
Abbreviation: NA, not available.
skin rash (in 66.2% of patients) and diarrhea (46.6%) in the 
gefitinib group and neuro-toxic effects (69.9%), neutropenia 
(67.1%) and alopecia (58.4%) in the carboplatin-paclitaxel 
group.
The favorable tolerance is particularly important for 
elderly patients or patients with comorbidities and poor PS. 
The INVITE trial showed a better safety profile for gefitinib 
as compared to vinorelbine in elderly patients.45 Only 9.6% 
had a dose interruption instead of the 21.9% in the chemo-
therapy group; with 21% of gefitinib patients that had a 
dose reduction versus 47.9% of vinorelbine arm. No toxic-
ity related death occurred in patients treated with gefitinib. 
In the INSTEP trial, patients with poor performance status 
treated with gefitinib experienced diarrhea (51%) and skin Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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rash (34%), but no toxicity lead to death.46 The treatment 
discontinuation rate was low (14%).
Quality of life
The aim of every treatment for advanced NSCLC is purely 
palliative, set to achieve a prolongation in survival   (whenever 
possible) and, above all, relief from disease symptoms with-
out additive side effects. This rationale led investigators to 
consider quality of life (QoL) as an important parameter and 
endpoint in the trials.
The first phase II trials, such as IDEAL-1 and 2, showed 
that gefitinib administration improved the QoL of treated 
patients, as demonstrated by the Functional Assessment 
of Cancer Therapy-Lung (FACT-L) questionnaire used 
to assess it. In fact, there was a demonstration of symp-
tom improvement rates of 40.3% and 43.1% in IDEAL-1 
and 2, respectively.26,27 Symptom improvement was rapid and 
correlated with tumor response and survival. In IDEAL-2, 
at the recommended gefitinib dose of 250 mg/day, median 
overall survival times were 13.6 and 4.6 months for patients 
with and without symptom improvement, respectively, and 
9.7 months for patients with symptom improvement with-
out tumor response.78 Among patients with stable disease 
or disease progression, those with symptom improvement 
had significantly better overall survival than those without 
improvement.
These data were confirmed by following trials, such as 
SIGN, INTEREST and V-15-32 studies.34–36 In the SIGN 
trial, in which symptom improvement was a primary 
endpoint, QoL and symptom improvement, evaluated by 
FACT-L, were greater with gefitinib than docetaxel (33.8% 
versus 26% and 36.8% versus 26%, respectively).34 In the 
INTEREST trial more patients treated with gefitinib obtained 
a statistically significant higher rate of improvement in 
QoL. In fact, FACT-L total score was 25.1% versus 14.7% 
(P , 0.0001) and FACT-L TOI (Trial Outcome Index) 
17.3% versus 10.3% (P = 0.0026), for gefitinib and doc-
etaxel, respectively. Similar proportion of patients improved 
their lung cancer symptoms (evaluated by FACT-L Lung 
Cancer Subscale) with gefitinib and docetaxel (20.4% versus 
16.8%, respectively).35 Finally, the V-15-32 trial showed 
a statistically significant improvement rate in terms of 
QoL in patients treated with gefitinib when compared with 
docetaxel.36,79 FACT-L total score was 23.4% versus 13.9% 
(P = 0.023) and TOI was 20.5% versus 8.7% (P = 0.002) for 
gefitinib and docetaxel, respectively. There were no signifi-
cant differences between treatments in LCS improvement 
rates (23% versus 20%, P = 0.562).
In the IPASS trial, QoL was one of the secondary 
  endpoints.69 Significantly more patients in the gefitinib group 
than those in the carboplatin-paclitaxel group had a clinically 
relevant improvement in QoL, assessed by scores on the 
FACT-L questionnaire (48% versus 40%; OR, 1.34, 95% CI, 
1.06–1.69, P = 0.01) and by scores on the TOI (46.4% versus 
32.8%; OR, 1.78, 95% CI, 1.40–2.26, P , 0.001). Rates of 
reduction in symptoms, assessed on the basis of the LCS 
scores, were similar between patients who received gefitinib 
and those who received carboplatin-paclitaxel (51.5% versus 
48.5%; OR, 1.13, 95% CI, 0.90–1.42, P = 0.30).
An agent that might improve QoL and give relief from 
symptoms without bringing heavy toxicity is particularly 
relevant for poor PS or elderly patients. For this reason QoL 
and pulmonary symptom relief were important parameters in 
INVITE and INSTEP trials.45,46 In the INVITE trial overall 
QoL improvement and pulmonary symptom improvement 
(PSI) rates were 24.3% and 36.6% (for gefitinib) and 10.9% 
and 31.0% (for vinorelbine), respectively.45 On the contrary, 
in the INSTEP trial no statistical difference was seen either 
for QoL improvement (21.1% versus 20%) and PSI (28.3% 
versus 28.3%) in patients treated with gefitinib or BSC.46
Conclusions
Gefitinib is a well tolerated anticancer agent proven to be 
effective in both chemotherapy-naive and pretreated NSCLC 
patients. Due to its efficacy and favorable toxicity profile, it 
can be considered as a treatment option for those patients 
who cannot receive standard chemotherapy because of age, 
comorbidities or poor performance status.
As evidenced by data obtained in the subgroup 
analysis of the IPASS and First-SIGNAL trials and by 
the results of WJTOG3405 and NEJ002 studies, specific 
  mutations of EGFR tyrosine kinase binding domain are 
related to an increased response rate and progression-free 
survival in patients treated with gefitinib compared to stan-
dard first-line chemotherapy treatment.
The discovery of these molecular predictors opens a new 
way in the management of advanced NSCLC, in which gefi-
tinib is expected to have its larger impact. In clinical practice, 
given the low rate of EGFR mutations in   Caucasian popula-
tion (10%–15%), mutation analysis should be recommended 
in those patients who present at least one of the clinical or 
pathological features, which are related to a higher prob-
ability of mutation, such as female gender, non-smoking 
history, Asian ethnicity and adenocarcinoma histology. In 
patients harboring EGFR mutation, an up-front treatment 
with gefitinib should be considered.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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EGFR-TKI resistance represents another major issue for 
research. The point mutation T790M of the EGFR gene and 
MET amplification are known to be involved in the majority 
of cases of acquired resistance to gefitinib. Open questions 
also remain for the potential use of gefitinib as maintenance 
therapy. As the trials undertaken so far were performed on 
unselected patients there is need to assess if gene mutated 
patients could derive a real benefit from a subsequent therapy 
with TKIs administered right after chemotherapy.
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